eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2024
vol. 28
 
Share:
Send email
Share:
abstract:
Original paper

A cohort of long-surviving patients affected by small and medium uveal melanoma treated with ruthenium-106 plaque brachytherapy

Concetta Laliscia
1
,
Franco Perrone
2
,
Francesca Guido
3
,
Federica Cresti
3
,
Taiusha Fuentes
1
,
Fabiola Paiar
1
,
Guglielmo Pellegrini
2
,
Federica Genovesi Ebert
2

  1. Department of New Technologies and Translational Research, Division of Radiation Oncology, University Hospital of Pisa, Pisa, Italy
  2. Department of Medical Physics, Division of Medical Physics, University Hospital of Pisa, Pisa, Italy
  3. Department of Ophthalmic Surgery, Division of Ophthalmic Surgery, University Hospital of Pisa, Pisa, Italy
Contemp Oncol (Pozn) 2024; 28 (4): 318–325
DOI: https://doi.org/10.5114/wo.2024.146992
Online publish date: 2025/01/15
View full text Get citation
 
PlumX metrics:
Introduction:
This study reports the long-term outcomes in patients affected by uveal melanoma (UM) treated with ruthenium-106 (106Ru) plaque bra­chytherapy (BT).

Material and methods:
From May 2005 to January 2024, 127 patients (median age: 69 years, range: 32–90 years) affected by small and medium UM were treated with 106Ru plaque BT at the University Hospital of Pisa. All the patients were treated with 106Ru plaque BT with a prescription dose of 110 Gy to the tumor apex.

Results:
Inclusion criteria comprised Eastern Cooperative Oncology Group performance status ≤ 2, life expectancy > 6 months, and tumor thickness ≤ 6 mm and/or diameter ≤ 16 mm. The 5-year rate of local control, progression-free survival, metastasis-free survival, and overall survival were 95.2%, 85.4%, 93.0%, and 95.9%, respectively. Local progression was recorded in nine patients (7.1%): two of them (1.6%) had also distant metastasis. Seven patients were retreated with photon beam and one patient with proton beam stereotactic radiosurgery; one patient was retreated with 125I plaque BT. Only one patient underwent enucleation for large local progression after about 10 years. Thirty-four patients (26.8%) had one or more acute and late toxicities. No grade 4 acute or late toxicity was reported.

Conclusions:
This study suggests that 106Ru plaque BT is a successful and well-tolerated radiotherapy technique in the management of UM.

keywords:

uveal melanoma, eye, bra­chytherapy plaque
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.